2 Big Reasons to Buy Kimberly-Clark

Recs

7

Be A Motley Fool Millionaire!

David Gardner's top pick took an epic run of 1,334%! See what he’s recommending that you buy NEXT.

Consumer stocks are now as risky as they've ever been. Unemployment’s historically high, consumers are spooked, and subpar earnings abound, as companies pay the price for lost competitive advantage or fiscal irresponsibility. But tough times can offer investors the best chance to buy stocks

Even if stock prices are low, investors still need to be careful. Many companies simply won't survive the recession in their current form. However, thinning the herd of weaker competitors should lead to big winners in the consumer space when the economy recovers.  I've already highlighted two reasons to sell consumer-staples company Kimberly-Clark (NYSE: KMB).  Here, I've listed two reasons to pull the "buy" trigger on this personal- and health-care company.

1. Showing shareholders the money
Manufacturer and marketer of well-known brands such as Kleenex, Kotex, Huggies, and Depends, Kimberly-Clark is one of the larger and better-known consumer-staples companies. Among other qualities, this sector often attracts investors with its substantial dividend yields, made possible by relatively stable cash flows, and in the case of more mature companies, modest capital expenditure requirements.

And compared to peers that compete in similar categories, Kimberly-Clark is clearly a dividend overachiever. Just take a gander at the table below.

Company

Market Cap

Dividend Yield

Payout Ratio

Kimberly-Clark

$24.6 B

4.1%

59.1%

Procter & Gamble (NYSE: PG)

$167.1 B

3.1%

37.5%

Colgate-Palmolive (NYSE: CL)

$39.3 B

2.2%

42.1%

Church & Dwight (NYSE: CHD)

$4.0 B

1.0%

11.7%

Johnson & Johnson (NYSE: JNJ)

$167.9 B

3.2%

40.7%

Energizer (NYSE: ENR)

$4.6 B

N/A

N/A

Data from CapitalIQ on Oct. 15.

Sure, that 4.1% dividend yield is appealing on an absolute basis, but theoretically, it also helps put a higher floor beneath the stock, should the market sell off. In other words, compared to competitors' shares, as the stock price falls, that yield will reach higher levels much more quickly, potentially drawing in buyers and supporting the price. Granted, the payout ratio exceeds that of peers, but it's hardly poised to be the next dividend blowup. All said, Kimberly-Clark's dividend presents a compelling, if succinct, reason to scoop up shares.

2. Head over heels for BRICIT
No, it's not a new super-absorbent paper product. In company lingo, BRICIT stands for Brazil, Russia, India, China, Indonesia, and Turkey. Together, that geography has been driving the company's growth. Representing a hefty 30% of 2008 net sales, the segment has been a strategic priority.

And for good reason: Five-year organic sales in those nations through 2008 grew at an annualized 11%, more than double the companywide 4.9%. A variety of new products and innovations no doubt helped segment performance hold up in the second quarter, with volume down slightly, but organic sales up 12% on stronger pricing.

With U.S. consumers no bastion of strength, and private-label goods posing an increasingly larger threat here, Kimberly-Clark's focus on the more earnest, more stable emerging-market consumer is arguably a flashing buy signal.

What do you think?
We've made our Foolish case on Kimberly-Clark -- now it's your turn. Is Kimberly-Clark a sound buy? Or do you have your doubts? Share your comments below.

Other faithfully Foolish buys:

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Kimberly-Clark, Johnson & Johnson, and Procter & Gamble are Motley Fool Income Investor recommendations. Energizer Holdings is a Stock Advisor selection. The Fool owns shares of Procter & Gamble. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Mike Pienciak owns shares of Church & Dwight, but he holds no beneficial interest in any other company mentioned in this article. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 16, 2009, at 2:55 PM, KevinNU7 wrote:

    Since all the other Global consumer products companies are also competing for BRICIT growth why is it labeled as a compelling reason to by KMB? It would have been nice for you to show how their growth is outpacing competition, or perhaps it is not?

  • Report this Comment On October 18, 2009, at 6:50 AM, f00lsgoldy wrote:

    NYSE highest dividend yielding stocks top 100:

    http://www.TopYields.nl/Top_dividend_yields_of_NYSE.php

  • Report this Comment On October 19, 2009, at 11:39 AM, Magic09 wrote:

    I agree with KevinNU7's comments and it may be too early to tell the future impact of the recent acquisitions to the Health Care Business Unit. They have not yet been integrated I Flow Corp, and Baylis Medical Co. as they are recent acquisitions.

    And they bought Jackson Safety, which had a storied past, so my fear is SG&A gets out of balance until that happens; increased margins will be coming from new acquisitions in industries KC did not have previous experience; and as long as we have a weak dollar BRICT will benefit. What happens when the dollar strengthens?

    Best time to buy this stock has passed (March 09 when the price bottomed).

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 1009589, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:05:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

12/1/2009 10:49 AM
JNJ $63.42 Up +0.58 +0.92%
Johnson & Johnson CAPS Rating: *****
PG $62.94 Up +0.59 +0.95%
The Procter & Gamb… CAPS Rating: *****
KMB $66.95 Up +0.98 +1.49%
Kimberly-Clark Cor… CAPS Rating: ****
ENR $57.36 Up +1.02 +1.81%
Energizer Holdings… CAPS Rating: ****
CL $85.42 Up +1.23 +1.46%
Colgate-Palmolive… CAPS Rating: ****
CHD $59.22 Up +0.18 +0.30%
Church & Dwight Co… CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!